Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy

被引：64

作者：

Rocino, Angiola ^{[1
]}

Coppola, Antonio ^{[2
]}

Franchini, Massimo ^{[3
]}

Castaman, Giancarlo ^{[4
,5
]}

Santoro, Cristina ^{[6
]}

Zanon, Ezio ^{[7
]}

Santagostino, Elena ^{[8
]}

Morfini, Massimo ^{[9
]}

机构：

[1] San Giovanni Bosco Hosp, Haemophilia & Thrombosis Ctr, Naples, Italy

[2] Federico II Univ Hosp, Reg Reference Ctr Coagulat Disorders, Naples, Italy

[3] Carlo Poma Hosp, Dept Transfus Med & Haematol, Mantua, Italy

[4] San Bortolo Hosp, Haemophilia & Thrombosis Ctr, Dept Haematol, Vicenza, Italy

[5] Careggi Univ Hosp, Ctr Bleeding Disorders, Florence, Italy

[6] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, I-00185 Rome, Italy

[7] Univ Padua, Sch Med, Haemophilia Ctr, Dept Cardiol Thorac & Vasc Sci, Padua, Italy

[8] IRCCS Ca Granda Fdn, Maggiore Hosp Policlin, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Milan, Italy

[9] Italian Assoc Haemophilia Centres AICE, Milan, Italy

来源：

BLOOD TRANSFUSION | 2014年 / 12卷 / 04期

关键词：

RECOMBINANT FACTOR-VIII; IMMUNE TOLERANCE INDUCTION; PREVIOUSLY UNTREATED PATIENTS; VON-WILLEBRAND-DISEASE; QUALITY-OF-LIFE; PREVIOUSLY TREATED PATIENTS; FACTOR-IX CONCENTRATE; FACTOR-XI DEFICIENCY; RARE COAGULATION DISORDERS; CREUTZFELDT-JAKOB-DISEASE;

D O I：

10.2450/2014.0223-14

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：575 / 598

页数：24

共 194 条

[1] Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) [J].

Abshire, T. C. ;

Federici, A. B. ;

Alvarez, M. T. ;

Bowen, J. ;

Carcao, M. D. ;

Gill, J. Cox ;

Key, N. S. ;

Kouides, P. A. ;

Kurnik, K. ;

Lail, A. E. ;

Leebeek, F. W. G. ;

Makris, M. ;

Mannucci, P. M. ;

Winikoff, R. ;

Berntorp, E. .

HAEMOPHILIA, 2013, 19 (01) :76-81

[2] Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia [J].

Abshire, Thomas .

SEMINARS IN HEMATOLOGY, 2008, 45 (02) :S3-S6

[3] Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues [J].

Aledort, L. M. .

HAEMOPHILIA, 2008, 14 (01) :39-43

[4] Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies [J].

Aledort, L. M. ;

Navickis, R. J. ;

Wilkes, M. M. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) :2180-2192

[5] Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].

Aledort, LM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708

[6] A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].

ALEDORT, LM ;

HASCHMEYER, RH ;

PETTERSSON, H ;

EIBL, H ;

GILBERT, M ;

HILGARTNER, M ;

KUNSHACK, M ;

LARRIEU, MJ ;

LEVINE, P .

JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399

[7]

[Anonymous], 2005, G U SERIE GEN, V85

[8]

[Anonymous], 2014, G U SERIE GEN, V72, P36

[9] Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [J].

Antunes, S. V. ;

Tangada, S. ;

Stasyshyn, O. ;

Mamonov, V. ;

Phillips, J. ;

Guzman-Becerra, N. ;

Grigorian, A. ;

Ewenstein, B. ;

Wong, W. -Y. .

HAEMOPHILIA, 2014, 20 (01) :65-72

[10] Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors [J].

Astermark, J. ;

Rocino, A. ;

Von Depka, M. ;

Van den Berg, H. M. ;

Gringeri, A. ;

Mantovani, L. G. ;

Morado, M. ;

Garrido, R. P. ;

Schiavoni, M. ;

Villar, A. ;

Windyga, J. .

HAEMOPHILIA, 2007, 13 (01) :38-45

← 1 2 3 4 5 6 7 8 9 10 →